STMN2 and Alzheimer disease: Analysis of the Mayo Clinic dataset showed a significant enrichment of STMN2 cryptic exon in the temporal cortex of Alzheimer’s disease patients compared to controls (Fig. 4d) and a significant decrease in full-length STMN2 only in Alzheimer’s disease patients with TDP-43 pathology compared to controls (Fig. 4e).